Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

Xu Qiao; Jiang Yu; Wan Shihao; He Yunfeng

doi:10.13406/j.cnki.cyxb.003298

您当前的位置：

首页 >

文章列表页 >

Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

Other tumors of urinary system | 更新时间：2025-10-21

- Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma
- Journal of Chongqing Medical University Vol. 48, Issue 8, Pages: 1000-1004(2023)
- 作者机构：
  
  重庆医科大学附属第一医院泌尿外科，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003298
  CLC： R730.5
- Received：11 May 2023，
  
  Revised：2023-06-22，
  
  Accepted：30 June 2023，
  
  Published：28 August 2023
- 稿件说明：
移动端阅览
许巧,姜宇,万士豪,等.维迪西妥单抗和术后化疗用于治疗人表皮生长因子受体2阳性的局限性尿路上皮癌患者的临床疗效分析[J].重庆医科大学学报,2023,48(8):1000-1004.

Xu Qiao,Jiang Yu,Wan Shihao,et al.Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma[J].Journal of Chongqing Medical University,2023,48(8):1000-1004.
许巧,姜宇,万士豪,等.维迪西妥单抗和术后化疗用于治疗人表皮生长因子受体2阳性的局限性尿路上皮癌患者的临床疗效分析[J].重庆医科大学学报,2023,48(8):1000-1004. DOI： 10.13406/j.cnki.cyxb.003298.

Xu Qiao,Jiang Yu,Wan Shihao,et al.Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma[J].Journal of Chongqing Medical University,2023,48(8):1000-1004. DOI： 10.13406/j.cnki.cyxb.003298.

摘要

目的

初步探索人表皮生长因子受体2（human epidermal growth factor receptor 2，Her-2）阳性的局限性尿路上皮癌患者术后辅助使用维迪西妥单抗的效果。

方法

回顾性分析32例术后辅助使用维迪西妥单抗的局限性尿路上皮癌患者（维迪西妥组）和104例术后使用传统化疗的患者（术后化疗组）临床资料，随访患者的复发情况，对比分析2组患者的复发率和不良反应率。

结果

2组患者的基线数据和术前术后的相关数据没有统计学差异（

0.05）。维迪西妥组患者术后1人复发，其复发率（9.4%）远远低于术后化疗组（20.2%）（

=0.007）。同时，维迪西妥组不良反应发生率（12.5%）低于术后化疗组（20.2%）（

=0.022）。

结论

术后治疗的12个月内，维迪西妥组患者与接受传统化疗的患者相比，复发率和不良反应率相对更低，提示维迪西妥在降低尿路上皮癌患者术后复发率和延缓疾病进展方面有探究意义。

Abstract

Objective

To explore the preliminary efficacy of Disitamab Vedotin（RC48） as postoperative adjuvant therapy in patients with Her-2 positive locally advanced urothelial carcinoma.

Methods

The clinical data of 32 postoperative patients who received adjuvant therapy with RC48（RC48 group） and 104 postoperative patients who received conventional chemotherapy for locally advanced urothelial carcinoma（chemotherapy group） were retrospectively analyzed. The recurrence status of patients was followed up. The recurrence rate and adverse reaction rate of the two groups were compared.

Results

There were no significant differences in baseline data and preoperative/postoperative data between the two groups（

0.05）. The recurrence rate（9.4%，1 case） of the RC48 group was significantly lower than that of the chemotherapy group（20.2%）（

=0.007）. The incidence of adverse reactions in the RC48 group（12.5%） was significantly lower than that in the chemotherapy group（20.2%）（

=0.022）.

Conclusion

Within 12 months of postoperative treatment，the recurrence rate and adverse reaction rate of patients in the RC48 group were lower than those in the conventional chemotherapy group，suggesting that RC48 has clinical significance in reducing the recurrence rate and delaying the progression of urothelial carcinoma in postoperative patients.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

Teoh JY ， Kamat AM ， Black PC ， et al . Recurrence mechanisms of non-muscle-invasive bladder cancer：a clinical perspective [J ] . Nat Rev Urol ， 2022 ， 19 （ 5 ）： 280 - 294 .

von der Maase H ， Sengelov L ， Roberts JT ， et al . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin，with methotrexate，vinblastine，doxorubicin，plus cisplatin in patients with bladder cancer [J ] . J Clin Oncol ， 2005 ， 23 （ 21 ）： 4602 - 4608 .

Cathomas R ， Lorch A ， Bruins HM ， et al . The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma [J ] . Eur Urol ， 2022 ， 81 （ 1 ）： 95 - 103 .

Vlachostergios PJ ， Faltas BM . Treatment resistance in urothelial carcinoma：an evolutionary perspective [J ] . Nat Rev Clin Oncol ， 2018 ， 15 （ 8 ）： 495 - 509 .

Sternschuss M ， Sarfaty M . Antibody-drug conjugates：a novel approach for the treatment of metastatic urothelial carcinoma [J ] . Harefuah ， 2022 ， 161 （ 1 ）： 49 - 54 .

Ravi P ， McGregor BA . Antibody-drug conjugates for the treatment of urothelial carcinoma [J ] . Expert Opin Biol Ther ， 2021 ， 21 （ 7 ）： 915 - 922 .

Shi F ， Liu YL ， Zhou XX ， et al . Disitamab vedotin：a novel antibody-drug conjugates for cancer therapy [J ] . Drug Deliv ， 2022 ， 29 （ 1 ）： 1335 - 1344 .

刘　磊，乐昶捷，张远鹏，等 . 高级别浸润性膀胱癌在维迪西妥单抗新辅助治疗后行根治性膀胱切除术1例 [J ] . 临床泌尿外科杂志， 2022 ， 37 （ 12 ）： 960 - 965 .

Liu L ， Le CJ ， Zhang YP ， et al . A case report of high-grade muscle-invasive bladder cancer undergoing radical cystectomy after neoadjuvant therapy with RC48 [J ] . J Clin Urol ， 2022 ， 37 （ 12 ）： 960 - 965 .

Patelli G ， Zeppellini A ， Spina F ， et al . The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer：a systematic review and future perspectives [J ] . Cancer Treat Rev ， 2022 ， 104 ： 102351 .

Ross JS ， Fletcher JA . The HER-2/neu oncogene：prognostic factor，predictive factor and target for therapy [J ] . Semin Cancer Biol ， 1999 ， 9 （ 2 ）： 125 - 138 .

Moasser MM . The oncogene HER2：its signaling and transforming functions and its role in human cancer pathogenesis [J ] . Oncogene ， 2007 ， 26 （ 45 ）： 6469 - 6487 .

Brandau S ， Böhle A . Bladder cancer. I. Molecular and genetic basis of carcinogenesis [J ] . Eur Urol ， 2001 ， 39 （ 5 ）： 491 - 497 .

Baffa R ， Letko J ， McClung C ， et al . Molecular genetics of bladder cancer：targets for diagnosis and therapy [J ] . J Exp Clin Cancer Res ， 2006 ， 25 （ 2 ）： 145 - 160 .

Disis ML ， Cheever MA . HER-2/neu protein：a target for antigen-specific immunotherapy of human cancer [J ] . Adv Cancer Res ， 1997 ， 71 ： 343 - 371 .

Waks AG ， Winer EP . Breast cancer treatment：a review [J ] . JAMA ， 2019 ， 321 （ 3 ）： 288 - 300 .

Marchiò C ， Annaratone L ， Marques A ， et al . Evolving concepts in HER2 evaluation in breast cancer：heterogeneity，HER2-low carcinomas and beyond [J ] . Semin Cancer Biol ， 2021 ， 72 ： 123 - 135 .

Manzano A ， Ocaña A . Antibody-drug conjugates：a promising novel therapy for the treatment of ovarian cancer [J ] . Cancers ， 2020 ， 12 （ 8 ）： 2223 .

Chau CH ， Steeg PS ， Figg WD . Antibody-drug conjugates for cancer [J ] . Lancet ， 2019 ， 394 （ 10200 ）： 793 - 804 .

Rai BP ， Luis Dominguez Escrig J ， Vale L ， et al . Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with haematuria [J ] . Eur Urol ， 2022 ， 82 （ 2 ）： 182 - 192 .

Alifrangis C ， McGovern U ， Freeman A ， et al . Molecular and histopathology directed therapy for advanced bladder cancer [J ] . Nat Rev Urol ， 2019 ， 16 （ 8 ）： 465 - 483 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances in antibody-drug conjugate in the treatment of urothelial carcinoma

Role of lidocaine in assisting the treatment of different types of tumor： basic and clinical evidence

CKLF-like MARVEL transmembrane domain-containing 6 promotes the proliferation，invasion，and migration of gastric cancer cells and inhibits apoptosis through targeted binding to human epidermal growth factor receptor 2

Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer

Predictive value of NLR and PLR for outcome after immunotherapy in advanced urothelial carcinoma

Related Author

Bai Xuesong

Yin Hubin

Kuang Youlin

Gou Xin

Zhao Jiahui

Han Yongzheng

Li Min

Liu Chang

Related Institution

Department of Anesthesiology，Peking University Third Hospital

Daytime Chemotherapy Center，The First Affiliated Hospital of Jinzhou Medical University

Department of Catheterization，The First Affiliated Hospital of Jinzhou Medical University

Department of Urology,Chongqing University Fuling Hospital

Department of Urology,The Second Affiliated Hospital of Chongqing Medical University

⁰